Boehringer Ingelheim’s Ofev (nintedanib) Receives Health Canada’s Approval as the First Therapy to Treat SSc-ILD in Canada

Boehringer Ingelheim’s Ofev (nintedanib) Receives Health Canada’s Approval as the First Therapy to Treat SSc-ILD in Canada

Shots:

  • Health Canada approved Ofev (nintedanib) as the first and only treatment, indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease
  • The approval is based P-III SENSCIS study assessing Ofev vs PBO in 576 patients with SSc-ILD across 32 countries including Canada, resulted in slowing loss of pulmonary function by 44% as measured by FVC over 52wks.
  • Ofev is a tyrosine kinase inhibitor, currently approved in 70+ countries including Canada for patients with idiopathic pulmonary fibrosis (IPF) and received FDA’s for approval for treating SSc-ILD

Click here to­ read full press release/ article | Ref: Newswire Canada | Image: Top Employers Institute